These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The Promise of PCSK9 and Lipoprotein(a) as Targets for Gene Silencing Therapies. Chan DC; Watts GF Clin Ther; 2023 Nov; 45(11):1034-1046. PubMed ID: 37524569 [TBL] [Abstract][Full Text] [Related]
5. Role of lipoprotein(a) in atherosclerotic cardiovascular disease: A review of current and emerging therapies. Alhomoud IS; Talasaz A; Mehta A; Kelly MS; Sisson EM; Bucheit JD; Brown R; Dixon DL Pharmacotherapy; 2023 Oct; 43(10):1051-1063. PubMed ID: 37464942 [TBL] [Abstract][Full Text] [Related]
6. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives. Wu MF; Xu KZ; Guo YG; Yu J; Wu Y; Lin LM Cardiovasc Drugs Ther; 2019 Dec; 33(6):739-748. PubMed ID: 31655942 [TBL] [Abstract][Full Text] [Related]
7. Lp(a): a New Pathway to Target? Nurmohamed NS; Kraaijenhof JM; Stroes ESG Curr Atheroscler Rep; 2022 Nov; 24(11):831-838. PubMed ID: 36066785 [TBL] [Abstract][Full Text] [Related]
9. Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review. Duarte Lau F; Giugliano RP JAMA Cardiol; 2022 Jul; 7(7):760-769. PubMed ID: 35583875 [TBL] [Abstract][Full Text] [Related]
10. Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease. Tada H; Takamura M; Kawashiri MA J Atheroscler Thromb; 2019 Jul; 26(7):583-591. PubMed ID: 31061262 [TBL] [Abstract][Full Text] [Related]
13. Lp(a) in the Pathogenesis of Aortic Stenosis and Approach to Therapy with Antisense Oligonucleotides or Short Interfering RNA. Di Costanzo A; Indolfi C; Franzone A; Esposito G; Spaccarotella CAM Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834387 [TBL] [Abstract][Full Text] [Related]
14. Consensus document on Lipoprotein(a) from the Italian Society for the Study of Atherosclerosis (SISA). Chiesa G; Zenti MG; Baragetti A; Barbagallo CM; Borghi C; Colivicchi F; Maggioni AP; Noto D; Pirro M; Rivellese AA; Sampietro T; Sbrana F; Arca M; Averna M; Catapano AL Nutr Metab Cardiovasc Dis; 2023 Oct; 33(10):1866-1877. PubMed ID: 37586921 [TBL] [Abstract][Full Text] [Related]
15. Lipoprotein(a) and Cardiovascular Disease: A Missing Link for Premature Atherosclerotic Heart Disease and/or Residual Risk. Melita H; Manolis AA; Manolis TA; Manolis AS J Cardiovasc Pharmacol; 2022 Jan; 79(1):e18-e35. PubMed ID: 34694242 [TBL] [Abstract][Full Text] [Related]
16. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. O'Donoghue ML; Rosenson RS; Gencer B; López JAG; Lepor NE; Baum SJ; Stout E; Gaudet D; Knusel B; Kuder JF; Ran X; Murphy SA; Wang H; Wu Y; Kassahun H; Sabatine MS; N Engl J Med; 2022 Nov; 387(20):1855-1864. PubMed ID: 36342163 [TBL] [Abstract][Full Text] [Related]
17. The Role of Antisense Therapies Targeting Lipoprotein(a). Plakogiannis R; Sorbera M; Fischetti B; Chen M J Cardiovasc Pharmacol; 2021 Jul; 78(1):e5-e11. PubMed ID: 34232223 [TBL] [Abstract][Full Text] [Related]